%0 Journal Article %A Meisam K. Arjmandi %A Derek Houston %A Yuanyuan Wang %A Laura C. Dilley %T Cochlear implant-related speech processing may diminish the advantage of exposure to infant-directed speech %D 2020 %R 10.1101/2020.06.29.20140319 %J medRxiv %P 2020.06.29.20140319 %X Caregivers modify their speech when talking to infants, a specific type of speech known as infant-directed speech (IDS). This speaking style facilitates language learning compared to adult-directed speech (ADS) in infants with normal hearing (NH). While infants with NH and those with cochlear implants (CIs) prefer listening to IDS over ADS, it is yet unknown how CI speech processing may affect the acoustic distinctiveness between ADS and IDS, as well as the degree of intelligibility of these. This study analyzed speech of seven female adult talkers to investigate the effects of simulated CI speech processing on (1) acoustic distinctiveness between ADS and IDS, (2) estimates of intelligibility of caregivers’ speech in ADS and IDS, and (3) individual differences in caregivers’ ADS-to-IDS modification and speech intelligibility. Results suggest that CI speech processing is substantially detrimental to the acoustic distinctiveness between ADS and IDS, as well as to the intelligibility benefit derived from ADS-to-IDS modifications. Moreover, the observed considerable variability across individual talkers in acoustic implementation of ADS-to-IDS modification and speech intelligibility was significantly reduced due to CI speech processing. The findings are discussed in the context of the link between IDS and language learning in infants with CIs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute on Deafness and other Communicative Disorders of the National Institutes of Health under award number R01DC008581 to D. Houston and L. Dilley, and the Dissertation Completion Award to Meisam K. Arjmandi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards of the Ohio State University and Michigan State University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in this study will be available upon request. %U https://www.medrxiv.org/content/medrxiv/early/2020/06/30/2020.06.29.20140319.full.pdf